Clinical trial
Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients…
NCT02047461 · Origin Biosciences, Industry · Completed
Key facts
| NCT number | NCT02047461 |
|---|---|
| Title | Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP |
| Official title | A Phase 2, Multicenter, Multinational, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of ORGN001 (Formerly ALXN1101) in Pediatric Patients With Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated With Recombinant Escherichia Coli-derived Cyclic Pyranopterin… |
| Lead sponsor | Origin Biosciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Molybdenum Cofactor Deficiency, Type A |
| Intervention type | Drug |
| Interventions | ORGN001 (formerly ALXN1101) |
| Enrollment | 8 |
| Start date | Apr 1, 2014 |
| Primary completion | Aug 1, 2022 |
| Completion | Oct 1, 2022 |
| First posted | Jan 28, 2014 |
| Last update posted | Oct 17, 2023 |
| Countries | Australia, Netherlands, Tunisia, United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: